Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
ObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established sever...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/full |
id |
doaj-6bd3049099ab435f963912d84afa04e0 |
---|---|
record_format |
Article |
spelling |
doaj-6bd3049099ab435f963912d84afa04e02020-12-08T08:33:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.585079585079Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In VivoZhi-Ran Yang0Zhi-Gao Chen1Xue-Mei Du2Yan Li3Yan Li4Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Research, Thorgene Co., Ltd., Beijing, ChinaDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established several patient-derived xenograft (PDX) models and primary cell lines of MPM. The cell lines were used to study the effects of apatinib on proliferation, cell cycle, migration, and apoptosis by CCK8, flow cytometry, wound-healing, Transwell, DAPI staining, and caspase-3 assays, respectively. For in vivo study, apatinib was delivered by gastric gavage into PDX models, and then efficacy and toxicity were determined by experimental peritoneal cancer index (ePCI) score and pathological examinations.ResultsOur results showed that apatinib significantly inhibited the proliferation and migration of MPM cells in vitro and induced cell cycle arrest. Studies on PDX models concurred that apatinib effectively suppressed subphrenic and liver invasions of nude mice. Moreover, histopathological analysis found that lymphocyte infiltration, coagulation necrosis and eosinophilic cell fragments were detected in tumor tissues after apatinib treatment. Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%).ConclusionsWe successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study.https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/fullmalignant peritoneal mesotheliomapatient-derived xenograft modelprimary cell linetoxicityapatinib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhi-Ran Yang Zhi-Gao Chen Xue-Mei Du Yan Li Yan Li |
spellingShingle |
Zhi-Ran Yang Zhi-Gao Chen Xue-Mei Du Yan Li Yan Li Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo Frontiers in Oncology malignant peritoneal mesothelioma patient-derived xenograft model primary cell line toxicity apatinib |
author_facet |
Zhi-Ran Yang Zhi-Gao Chen Xue-Mei Du Yan Li Yan Li |
author_sort |
Zhi-Ran Yang |
title |
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo |
title_short |
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo |
title_full |
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo |
title_fullStr |
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo |
title_full_unstemmed |
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo |
title_sort |
apatinib mesylate inhibits the proliferation and metastasis of epithelioid malignant peritoneal mesothelioma in vitro and in vivo |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-12-01 |
description |
ObjectiveMalignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo.MethodsWe established several patient-derived xenograft (PDX) models and primary cell lines of MPM. The cell lines were used to study the effects of apatinib on proliferation, cell cycle, migration, and apoptosis by CCK8, flow cytometry, wound-healing, Transwell, DAPI staining, and caspase-3 assays, respectively. For in vivo study, apatinib was delivered by gastric gavage into PDX models, and then efficacy and toxicity were determined by experimental peritoneal cancer index (ePCI) score and pathological examinations.ResultsOur results showed that apatinib significantly inhibited the proliferation and migration of MPM cells in vitro and induced cell cycle arrest. Studies on PDX models concurred that apatinib effectively suppressed subphrenic and liver invasions of nude mice. Moreover, histopathological analysis found that lymphocyte infiltration, coagulation necrosis and eosinophilic cell fragments were detected in tumor tissues after apatinib treatment. Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%).ConclusionsWe successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study. |
topic |
malignant peritoneal mesothelioma patient-derived xenograft model primary cell line toxicity apatinib |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/full |
work_keys_str_mv |
AT zhiranyang apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo AT zhigaochen apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo AT xuemeidu apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo AT yanli apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo AT yanli apatinibmesylateinhibitstheproliferationandmetastasisofepithelioidmalignantperitonealmesotheliomainvitroandinvivo |
_version_ |
1724390957275676672 |